|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C12N 15/11 | |
| C07H 21/04 | |||
| A61K 31/7088 |
| (11) | Number of the document | 1819365 |
| (13) | Kind of document | T |
| (96) | European patent application number | 05853546.9 |
| Date of filing the European patent application | 2005-12-09 | |
| (97) | Date of publication of the European application | 2007-08-22 |
| (45) | Date of publication and mention of the grant of the patent | 2014-07-02 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2005/044662 |
| Date | 2005-12-09 |
| (87) | Number | WO 2006/063252 |
| Date | 2006-06-15 |
| (30) | Number | Date | Country code |
| 634849 P | 2004-12-09 | US |
| (72) |
DE FOUGEROLLES, Antonin, US
|
| (73) |
Alnylam Pharmaceuticals Inc.,
300 Third Street, Cambridge, MA 02142,
US
Hartmann, Gunther, Noestrasse 19, 81479 München, DE Hornung, Veit, Martinshofstr. 16, 82049 Pullach, DE Endres, Stefan, Osterwaldstrasse 58, 80805 München, DE |
| (54) | Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs |
| Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs |